In a mid-stage study, 13 of 15 patients who received Soliris did not require further treatment for aHUS. Based on some back-of-the-envelope math based on the incidence of aHUS in France and Italy, Sanford C.
FORBES: $500,000-A-Year Drug Is Bright Light For Pharma